JIROborn
Financiado
Unravelling the role of Pneumocystis jirovecii in utero infection in early and l...
Unravelling the role of Pneumocystis jirovecii in utero infection in early and late pulmonary diseases of very preterm infants.
Very preterm birth represent about 1% of livebirths in Europe each year and is associated with 58% of neonatal deaths and substantial lifetime health problems. Pneumocystis jirovecii is an ubiquitous microfungus commonly known for...
Very preterm birth represent about 1% of livebirths in Europe each year and is associated with 58% of neonatal deaths and substantial lifetime health problems. Pneumocystis jirovecii is an ubiquitous microfungus commonly known for causing a severe interstitial
pneumonia in immunosuppressed subjects. However, this could be the tip of the iceberg and compelling new evidences suggest that
this infection may be pathogenic to certain groups of infants.
In utero transmission of P. jirovecii in humans has been recently proven. The fungus has been found in the lungs of 14-25%
preterm newborns, associated with an increased risk of respiratory distress syndrome (RDS) and bronchopulmonary dysplasia. The
ability of P. jirovecii to change the pulmonary environment has been demonstrated in other contexts, inducing a modification of the
host immune response, pulmonary dysbiosis and thickening of pulmonary alveoli. Genetic polymorphisms have also been
independently implicated in both an increased risk of preterm bi or neonatal RDS and a susceptibility to P. jirovecii.
Hence, JIROborn aims to address the impact of P. jirovecii in utero infection on the preterm infants’ lungs alteration and on the
development of subsequent early or late diseases, constructing a predictive model for monitoring preterm infants’ related
pulmonary complications.
JIROborn is a nested case control study using a prospective cohort of 596 infected and uninfected preterm infants and their mothers.
First, the clinical impact of P. jirovecii infection will be evaluated for early and later lung complications. Then, biological effects of the
infection will be studied focusing on the immune parameters, the microbiota and on surfactant and mucus production. Genetic and
epigenetic susceptibilities to P. jirovecii colonization and/or to the development of pulmonary diseases will be evaluated. Finally, all
data will be analysed to build a predictive model for the monitoring of preterm infants’ pulmonary complications.
ver más
Duración del proyecto: 25 meses
Fecha Inicio: 2024-04-05
Fecha Fin: 2026-05-31
Fecha Fin: 2026-05-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-05
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2023-PF-01-01:
MSCA Postdoctoral Fellowships 2023
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
181K€
Líder del proyecto
UNIVERSIDAD DE SEVILLA
No se ha especificado una descripción o un objeto social para esta compañía.
Total investigadores
3670
Total investigadores
3670